LFB offers to take GTC private; OncoGenex prices $50 million offering; mice "smell" light;

 @FierceBiotech: Sanofi will attend Harvard in hunt for new blockbusters. Article| Follow @FierceBiotech

 @JohnCFierce:Peregrine brain cancer drug more than triples survival rate--vs non-treatment--for 14 patients in mid-stage study. Article | Follow @JohnCFierce

Special Report: Pharma's Biggest Flops. Report

> LFB Biotechnologies is offering to take Framingham, MA-based GTC private at 28 cents a share. The buyout would come at a cost of $17 million. LFB release

> OncoGenex Pharmaceuticals has priced a $50 million offering of shares. The company intends to use the net proceeds from the offering primarily to advance its product pipeline, including its lead program, custirsen, and OGX-427, which is currently in clinical development as a treatment for prostate cancer and bladder cancer. OncoGenex release

> Shares of the struggling Cell Therapeutics popped this morning after the developer announced that the EMA had agreed to its plans for testing the cancer drug Pixuvri in children. Story

> Researchers have developed a new genetic tool in mice to speed the discovery of novel genes involved in cancer. They're calling it PiggyBac, and it provides biological validation to human mutations identified by cancer genome sequencing. Article

> The FDA's Office of Criminal Investigation is now joined in the congressional spotlight by the Government Accountability Office, which had been sent to investigate it. The case provides a rare glimpse of the GAO on the receiving end of a Charles Grassley-initiated probe. Story

And Finally... Harvard University neurobiologists have created mice that can "smell" light. Release

Suggested Articles

In this week's EuroBiotech Report, Roche's risdiplam clears another phase 3 SMA trial, Merck KGaA spinout raises cash and Korean VCs back PDC*line.

In our EuroBiotech roundup this week, a liver disease biotech raises €11 million, Autolus offers stock and Abivax plans midphase trial. 

Merck KGaA spinout iOnctura has raised a €15 million series A round to support an early-phase solid tumor trial of a PI3Kδ inhibitor.